Search

Displaying results 1081 - 1090 of 7062 in total
  1. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    It is produced by recombinant DNA technology using a mammalian cell expression system. … A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818].

  2. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    ], which are derivatives of [vitamin A]. … [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission

  3. Drug

    Mechlorethamine

    go.drugbank.com/drugs/DB00888
    ApprovedInvestigational

    A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. … The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Enalapril

    go.drugbank.com/drugs/DB00584
    ApprovedInvestigationalVet approved

    It was developed from a targeted research programmed using molecular modelling. … It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension.

    Mixtures: ENALAPRIL 1A PL 20/6MG, ENALAPRIL 1A PL 20/6MGProducts: ENALAPRIL 5 1A PHARMA, ENALAPRIL 10 1A PHARMA
  5. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. … Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy

  6. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because … Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007

  7. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101]. … Human albumin is a small globular protein (molecular weight: 66.5 kDa), consisting of a single chain of 585 amino acids organized in three repeated homolog domains (sites I, II, and III).

  8. Drug

    Pectin

    go.drugbank.com/drugs/DB11158
    ApprovedInvestigationalVet approved

    Under the FDA regulation, pectin qualifies as a GRAS (generally recognized as safe) food substance. This status allows pectin to be used with no limitations.[L1960] … Pectin is a heteropolysaccharide commercially derived from the cell wall of higher plants.[A32327] It is composed of partially methylated polygalacturonic acid units linked in the positions 1-4.

    Mixtures: Benylin DM With Pectin Freezer PopsCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. … approved by certain organizations like the European Medicines Agency [L2079].

  10. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.

    Mixtures: XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA, XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA